25821 INDUSTRIAL BLVD., SUITE 100, HAYWARD, CA
Market cap: $1.7M (12/25/2025)
Price: $1.61
Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Growth Backed By $90M+ Financing Package
Secures BARDA Meeting for Entolimod™ for Acute Radiation Syndrome
Financial Results, Costs of Shutting Down or Selling Parts of the Business, Reg. FD
Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS)
Executive Employment Agreement with Jennifer Ernst Effective October 8, 2025
Other Events
Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers
Reports Second Quarter 2025 Financial Results
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Effectiveness Notice
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Withdrawal of Offering Statement
Amended Offering Statement
Offering Statement
Correspondence